2024-03-29T11:53:21Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00020869
2022-12-15T03:51:33Z
453:456
471:537:538:1172
Cytokeratin in Cerebrospinal Fluid of Patients with Intracranial Tumors
抗サイトケラチンモノクロナール抗体を用いた脳腫瘍の髄液診断に関する研究
抗サイトケラチンモノクロナール抗体を用いた脳腫瘍の髄液診断に関する研究
河野, 充夫
128375
Cytokeratin
Monoclonal antibody
Intermediate filament
Brain tumor
サイトケラチン
モノクロナール抗体
中間径フィラメント
脳腫瘍
A new assay system for cytokeratin (CK) in cerebrospinal fluid (CSF) of patients with intracranial tumors was established. Antiboby KWS-1 was a murine monoclonal immunoglobulin generated from a fusdion of a mouse myeloma cell line with lymphocytes from a mouse immunised with the cytoskeleton from established human 1arge cell carcinoma cell line. KWS-1 was of IgG_1 subclass . KSW-1 antibody as characterized by immunoblotting identified CK subunit molecular weight at 56, 54, 52.5, 46, 45 and 40 Kd and did not cross react with other intermediate sized filament proteins. Extensive assesment by immunoperoxidase staining on formalin or ethanol fixed paraffin embedded human tissue sections showed wide reactivity in varieties of epithelial cells and tumors. An amplified sandwich assay was developed for the measurment of CK. Lower limit of antigen detection of this assay was at 50 ng/ml. CK in CSF of 57 patients with intracranial tumors and 14 non-neoplastic intracranial diseases were measured. CK levels were elevated in metastatic carcinoma (5/20), epidermoid (1/3), epidermoid carcinoma (1/1) and germ cell tumor (1/4), but under lower limit in other primary brain tumors and non-nepolastic intracranial diseases. These findings suggested that the measurement of CK in CSF may be a useful tumor marker in patients with metastatic carcinoma and some primary intracranial epithelial tumors.
departmental bulletin paper
新潟医学会
1992-07
application/pdf
新潟医学会雑誌
7
106
603
611
新潟医学会雑誌
AN00182415
00290440
https://niigata-u.repo.nii.ac.jp/record/20869/files/106(07)_603-611.pdf
jpn